Compare Stocks Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities. Stocks to Compare Sections All Sections Selected Performance Chart Price & Volume MarketRank Analyst Ratings Sales & Book Value Profitability & Earnings Dividends Debt Ownership Miscellaneous Headlines About Compare NASDAQ:ANIP OTCMKTS:BPMUF NASDAQ:CYTK NASDAQ:FIXX NASDAQ:FREQ On This Page Performance ChartPrice & VolumeMarketRank™Analyst RatingsSales & Book ValueProfitability & EarningsDividendsDebtOwnershipMiscellaneousHeadlinesAbout Comparison Ideas Stock Ideas Comparative Price Performance Over Time1 day7 days30 days90 days365 daysCompare Price & VolumeCompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's VolumeANIPANI Pharmaceuticals$64.96-1.7%$63.31$52.50▼$77.00$1.43B0.57316,339 shs218,680 shsBPMUFBasilea Pharmaceutica$61.34$53.46$47.50▼$61.34$807.85M0.290 shsN/ACYTKCytokinetics$37.01+1.1%$32.73$29.31▼$61.38$4.37B0.591.53 million shs960,448 shsFIXXHomology Medicines$1.18$0.46▼$17.51$978.01M-0.1390,307 shs22,300 shsFREQFrequency Therapeutics$0.30$0.58$0.18▼$16.00$10.94M0.84822,537 shs309,164 shsThese 7 Stocks Will Be Magnificent in 2025Discover the next wave of investment opportunities with our report, 7 Stocks That Will Be Magnificent in 2025. Explore companies poised to replicate the growth, innovation, and value creation of the tech giants dominating today's markets.Get This Free ReportCompare Price PerformanceCompany1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year PerformanceANIPANI Pharmaceuticals-1.72%-0.51%+3.47%-4.64%+4.14%BPMUFBasilea Pharmaceutica0.00%0.00%+6.31%+13.59%+27.39%CYTKCytokinetics+1.15%+9.17%+11.78%-4.24%-32.62%FIXXHomology Medicines0.00%0.00%0.00%0.00%0.00%FREQFrequency Therapeutics0.00%0.00%0.00%0.00%0.00%Compare MarketRank™CompanyOverall ScoreAnalyst's OpinionShort Interest ScoreDividend StrengthESG ScoreNews and Social Media SentimentCompany OwnershipEarnings & ValuationANIPANI Pharmaceuticals3.6667 of 5 stars2.51.00.03.32.13.31.3BPMUFBasilea PharmaceuticaN/AN/AN/AN/AN/AN/AN/AN/ACYTKCytokinetics4.0728 of 5 stars4.51.00.04.62.10.80.0FIXXHomology Medicines0.662 of 5 stars0.00.00.04.80.60.80.6FREQFrequency TherapeuticsN/AN/AN/AN/AN/AN/AN/AN/ACompare Analyst ForecastsCompanyConsensus Rating ScoreConsensus RatingConsensus Price Target% Upside from Current PriceANIPANI Pharmaceuticals 3.00Buy$78.8821.42% UpsideBPMUFBasilea Pharmaceutica 4.00Strong BuyN/AN/ACYTKCytokinetics 2.93Moderate Buy$70.9291.63% UpsideFIXXHomology Medicines 0.00N/AN/AN/AFREQFrequency Therapeutics 0.00N/AN/AN/ACurrent Analyst Ratings BreakdownLatest ANIP, FREQ, FIXX, CYTK, and BPMUF Analyst RatingsDateCompanyBrokerageActionRatingPrice TargetDetails7/10/2025ANIPANI PharmaceuticalsHC WainwrightSubscribe to MarketBeat All Access for the recommendation accuracy ratingInitiated CoverageBuy$84.006/9/2025CYTKCytokineticsJPMorgan Chase & Co.Subscribe to MarketBeat All Access for the recommendation accuracy ratingLower Price TargetOverweight ➝ Overweight$71.00 ➝ $53.005/29/2025CYTKCytokineticsMizuhoSubscribe to MarketBeat All Access for the recommendation accuracy ratingLower Price TargetOutperform ➝ Outperform$103.00 ➝ $84.005/14/2025CYTKCytokineticsNeedham & Company LLCSubscribe to MarketBeat All Access for the recommendation accuracy ratingReiterated RatingBuy ➝ Buy$72.00 ➝ $72.005/13/2025CYTKCytokineticsCantor FitzgeraldSubscribe to MarketBeat All Access for the recommendation accuracy ratingUpgradeStrong-Buy5/12/2025ANIPANI PharmaceuticalsGuggenheimSubscribe to MarketBeat All Access for the recommendation accuracy ratingReiterated RatingBuy ➝ Buy$86.00 ➝ $86.005/8/2025CYTKCytokineticsBarclaysSubscribe to MarketBeat All Access for the recommendation accuracy ratingLower Price TargetOverweight ➝ Overweight$55.00 ➝ $53.005/7/2025CYTKCytokineticsRoyal Bank Of CanadaSubscribe to MarketBeat All Access for the recommendation accuracy ratingLower Price TargetOutperform ➝ Outperform$82.00 ➝ $80.005/7/2025CYTKCytokineticsCitigroupSubscribe to MarketBeat All Access for the recommendation accuracy ratingLower Price TargetBuy ➝ Buy$86.00 ➝ $80.005/2/2025CYTKCytokineticsUBS GroupSubscribe to MarketBeat All Access for the recommendation accuracy ratingLower Price TargetNeutral ➝ Neutral$47.00 ➝ $41.005/2/2025CYTKCytokineticsNeedham & Company LLCSubscribe to MarketBeat All Access for the recommendation accuracy ratingReiterated RatingBuy ➝ Buy$72.00 ➝ $72.00(Data available from 7/12/2022 forward. View 10+ years of historical ratings with our analyst ratings screener.)Compare Sales & Book ValueCompanyAnnual RevenuePrice/SalesCashflowPrice/CashBook ValuePrice/BookANIPANI Pharmaceuticals$614.38M2.29$7.47 per share8.70$19.11 per share3.40BPMUFBasilea Pharmaceutica$236.92M3.41$6.85 per share8.96$6.99 per share8.78CYTKCytokinetics$18.47M239.31N/AN/A($1.15) per share-32.18FIXXHomology Medicines$1.16M0.00N/AN/A$1.26 per share0.00FREQFrequency Therapeutics$14.07M0.78N/AN/A$1.96 per share0.15Compare Profitability & EarningsCompanyNet IncomeEPSTrailing P/E RatioForward P/E RatioP/E GrowthNet MarginsReturn on Equity (ROE)Return on Assets (ROA)Next Earnings DateANIPANI Pharmaceuticals-$18.52M-$1.27N/A15.43N/A-3.12%21.35%7.52%8/5/2025 (Estimated)BPMUFBasilea Pharmaceutica$88.14MN/A0.00∞N/AN/AN/AN/A8/11/2025 (Estimated)CYTKCytokinetics-$589.53M-$5.29N/AN/AN/A-3,201.47%N/A-43.75%8/6/2025 (Estimated)FIXXHomology Medicines-$112.96M-$1.96N/AN/AN/A-4,779.31%-102.52%-74.91%N/AFREQFrequency Therapeutics-$81.58M-$1.89N/AN/AN/AN/A-107.67%-61.40%N/ALatest ANIP, FREQ, FIXX, CYTK, and BPMUF EarningsDateQuarterCompanyConsensus EstimateReported EPSBeat/MissGap EPSRevenue EstimateActual RevenueDetails8/5/2025Q2 2025ANIPANI Pharmaceuticals$1.49N/AN/AN/A$187.18 millionN/A5/9/2025Q1 2025ANIPANI Pharmaceuticals$1.37$1.70+$0.33$0.69$179.75 million$197.12 million5/6/2025Q1 2025CYTKCytokinetics-$1.41-$1.36+$0.05-$1.36$2.77 million$1.60 millionCompare DividendsCompanyAnnual PayoutDividend Yield3-Year Dividend GrowthPayout RatioYears of Consecutive GrowthANIPANI PharmaceuticalsN/AN/AN/AN/AN/ABPMUFBasilea PharmaceuticaN/AN/AN/AN/AN/ACYTKCytokineticsN/AN/AN/AN/AN/AFIXXHomology MedicinesN/AN/AN/AN/AN/AFREQFrequency TherapeuticsN/AN/AN/AN/AN/ACompare DebtCompanyDebt-to-Equity RatioCurrent RatioQuick RatioANIPANI Pharmaceuticals1.462.661.98BPMUFBasilea Pharmaceutica1.184.854.16CYTKCytokineticsN/A5.995.99FIXXHomology MedicinesN/A7.257.25FREQFrequency TherapeuticsN/A5.815.81Compare OwnershipInstitutional OwnershipCompanyInstitutional OwnershipANIPANI Pharmaceuticals76.05%BPMUFBasilea PharmaceuticaN/ACYTKCytokineticsN/AFIXXHomology Medicines31.32%FREQFrequency Therapeutics13.18%Insider OwnershipCompanyInsider OwnershipANIPANI Pharmaceuticals11.10%BPMUFBasilea PharmaceuticaN/ACYTKCytokinetics2.70%FIXXHomology Medicines16.10%FREQFrequency Therapeutics16.80%Compare Miscellaneous StatsCompanyEmployeesShares OutstandingFree FloatOptionableANIPANI Pharmaceuticals60021.66 million19.26 millionOptionableBPMUFBasilea Pharmaceutica14713.17 millionN/ANot OptionableCYTKCytokinetics250119.43 million116.20 millionOptionableFIXXHomology Medicines758.13 million48.77 millionOptionableFREQFrequency Therapeutics4636.52 million30.39 millionNot OptionableANIP, FREQ, FIXX, CYTK, and BPMUF HeadlinesRecent News About These CompaniesBRENIG THERAPEUTICS ANNOUNCES APPOINTMENTS OF DAVID L. LUCCHINO AS CEO AND TIEN DAM, M.D., AS CHIEF MEDICAL OFFICER, EXPANDS PIPELINEJuly 10 at 9:01 AM | tmcnet.comTransform with 528Hz Frequency 🔊June 30, 2025 | msn.comSecret Billionaire Frequency Launches Official Website Update Showcasing 7-Minute Daily Audio Program to Support Wealth Mindset and Mental ClarityJune 24, 2025 | finance.yahoo.comMolecular Response to Therapy Linked With Event-Free Survival in PVMay 23, 2025 | ajmc.comAIn uncertain times, focus on the mission, Cognito Therapeutics leaders sayApril 16, 2025 | medicaldesignandoutsourcing.comMTrevi Therapeutics RIVER trial meets primary endpointMarch 10, 2025 | markets.businessinsider.comTrevi Therapeutics RIVER trial meets primary endpointMarch 10, 2025 | markets.businessinsider.comProgentos Therapeutics CEO Chris Loose named board member and chair of the Fellowship and Programs Council for Hertz FoundationFebruary 27, 2025 | eurekalert.orgEKRRO stock touches 52-week low at $29.8 amid yearly slumpFebruary 11, 2025 | msn.compay n play casino trustlyDecember 29, 2024 | bwdisrupt.businessworld.inBSilence Therapeutics Advances Promising siRNA Therapy for PVDecember 10, 2024 | markets.businessinsider.comFrequency Exchange and gethealthy.store Launch "Nikki" Wellness Technology Into 1,000+ Clinic StoresDecember 5, 2024 | finance.yahoo.comFrequency Exchange Welcomes Former NHL Star and Current President of the Boston Bruins Cam Neely to Its Advisory BoardNovember 22, 2024 | finance.yahoo.comCognito Therapeutics highlights cost-effectiveness of neuromod for Alzheimer’sNovember 20, 2024 | massdevice.comLeamington hospital launches revolutionary robotic prostate treatment therapy for menNovember 14, 2024 | msn.comPromising Developments at Astria Therapeutics Bolster Buy RecommendationNovember 14, 2024 | markets.businessinsider.comStudy finds Tetris-based therapy can ease post-traumatic stress disorder symptomsNovember 14, 2024 | msn.com‘Most depressing, low-energy, low-frequency city:’ Kolkata India’s ‘dirtiest city’ says X user, triggering heated debate onlineNovember 7, 2024 | timesofindia.indiatimes.comRapport Therapeutics Reports Third Quarter Financials and Provides Business UpdateNovember 7, 2024 | markets.businessinsider.comModulating CD39 expression to enhance CAR-T cell therapy against hepatocellular carcinomaNovember 5, 2024 | news-medical.netNNew MarketBeat Followers Over TimeMedia Sentiment Over TimeANIP, FREQ, FIXX, CYTK, and BPMUF Company DescriptionsANI Pharmaceuticals NASDAQ:ANIP$64.96 -1.14 (-1.72%) Closing price 07/11/2025 04:00 PM EasternExtended Trading$64.94 -0.02 (-0.04%) As of 07/11/2025 04:20 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.ANI Pharmaceuticals, Inc., a biopharmaceutical company, develops, manufactures, and markets branded and generic prescription pharmaceuticals in the United States and Canada. The company manufactures oral solid dose products; semi-solids, liquids, and topicals; controlled substances; and potent products, as well as performs contract development and manufacturing of pharmaceutical products. It markets its products through retail pharmacy chains, wholesalers, distributors and mail order pharmacies, group purchasing organizations, specialty pharmacies, and hospitals. ANI Pharmaceuticals, Inc. was incorporated in 2001 and is headquartered in Baudette, Minnesota.Basilea Pharmaceutica OTCMKTS:BPMUF$61.34 0.00 (0.00%) As of 07/11/2025Basilea Pharmaceutica AG, a commercial-stage biopharmaceutical company, focuses on the development of products that address the medical needs in the therapeutic areas of oncology and anti-infectives. The company offers Cresemba, an intravenous and antifungal drug for the treatment of invasive aspergillosis and mucormycosis in the United States, and the European Union. It also offers medicine drug for invasive fungal infections. In addition, the company provides Zevtera, an antibiotic for the treatment of community and hospital-acquired pneumonia, as well as offers treatment of acute bacterial skin and skin structure infections, and Staphylococcus aureus bacteremia. Further, it offers Fosmanogepix, an antifungal drug for the treatment of Candidemia which in Phase II clinical trials. Basilea Pharmaceutica AG was founded in 2000 and is headquartered in Allschwil, Switzerland.Cytokinetics NASDAQ:CYTK$37.01 +0.42 (+1.15%) Closing price 07/11/2025 04:00 PM EasternExtended Trading$35.93 -1.08 (-2.92%) As of 07/11/2025 07:45 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.Cytokinetics, Incorporated, a late-stage biopharmaceutical company, focuses on discovering, developing, and commercializing muscle activators and inhibitors as potential treatments for debilitating diseases. The company develops small molecule drug candidates primarily engineered to impact muscle function and contractility. Its drug candidates include omecamtiv mecarbil, a novel cardiac myosin activator that is in Phase III clinical trial in patients with heart failure. The company also develops CK-136, a novel cardiac troponin activator that is in Phase I clinical trial; CK-586, a small molecule cardiac myosin inhibitor, that is in Phase I clinical trial; and aficamten, a novel cardiac myosin inhibitor, which is in Phase III clinical trial for the treatment of patients with symptomatic obstructive hypertrophic cardiomyopathy. Cytokinetics, Incorporated has a strategic alliance with Ji Xing Pharmaceuticals Limited. The company was incorporated in 1997 and is headquartered in South San Francisco, California.Homology Medicines NASDAQ:FIXXHomology Medicines, Inc., a genetic medicines company, focuses on transforming the lives of patients suffering from rare genetic diseases in the United States. The company offers proprietary platform is designed to utilize its human hematopoietic stem cell derived adeno-associated virus vectors (AAVHSCs) to deliver genetic medicines in vivo either through a nuclease-free gene editing mobility, gene therapy or for various genetic disorders. Its earlier stage product candidates comprising HMI-202, an investigational gene therapy which completed IND-enabling studies for the treatment of metachromatic leukodystrophy; and HMI-104 which completed IND-enabling studies. Homology Medicines, Inc. was incorporated in 2015 and is headquartered in Bedford, Massachusetts.Frequency Therapeutics NASDAQ:FREQFrequency Therapeutics, Inc., a clinical-stage biotechnology company, focuses on developing therapeutics to activate a person's innate regenerative potential to restore function. Its Progenitor Cell Activation approach uses small molecules to activate progenitor cells within the body to create functional tissue. The company's lead product candidate is FX-322, which is in Phase IIb clinical trial to treat the underlying cause of sensorineural hearing loss. It is also developing medicines for patients across a range of degenerative conditions, including multiple sclerosis, and diseases of the muscle, gastrointestinal tract, skin, and bone. The company has a license and collaboration agreement with Astellas Pharma Inc. for the development and commercialization of FX-322, as well as collaboration and licensing agreements with Massachusetts Eye and Ear, the Massachusetts Institute of Technology, and The Scripps Research Institute. Frequency Therapeutics, Inc. was incorporated in 2014 and is headquartered in Lexington, Massachusetts. More Stock Comparisions from MarketBeat Stock Comparison Ideas (A-K)5GAgricultureAirlineAmerica FirstApparelArtificial IntelligenceAutomotiveBankBiotechBitcoinBlockchainBlue ChipCanadianCannabisCasinoChatGPTChineseCloud StorageCryptocurrencyCybersecurityDefenseDividendDow 30EcommerceElectric VehiclesEnergyEntertainmenteSportsEV ChargingFertilizerGoldGroceryGrowthHealthcareHigh DividendHotelStock Comparison Ideas (L-Z)Large CapLeisureLithiumMagnificent SevenMega CapMemeMetaverseMid CapMiningMusic IndustryNanotechnologyNFTNuclear EnergyOilPharmaceuticalQuantum ComputingRenewable EnergyRestaurantRetailSemiconductorSocial MediaSolarSpaceTechnologyTelecomToyUtilityVideo GameVirtual RealityWallStreetBets More Stock Ideas from MarketBeat Stock Lists 5G Stocks Biotech Stocks Blue Chip Stocks DOW 30 Stocks FAANG Stocks Gold Stocks Large Cap Stocks Lumber Stocks Marijuana Stocks Micro Cap Stocks Oil Stocks REITs Small Cap Stocks SPACs Travel Stocks Trillion Dollar Stocks Water Stocks Warren Buffett Stocks Low Priced Stocks Penny Stock List Popular Penny Stocks Top Stocks Today Stocks on Sale Stocks Under $0.05 Stocks Under $0.10 Stocks Under $0.25 Stocks Under $0.50 Stocks Under $1 Stocks Under $2 Stocks Under $3 Stocks Under $5 Stocks Under $10 Stocks Under $20 Stocks Under $30 Stocks Under $50 Stocks By Exchange NASDAQ Stocks NYSE Stocks NYSEAMERICAN Stocks NYSEARCA Stocks NYSEMKT Stocks OTCMKTS Stocks TSX Stocks TSXV Stocks LSE Stocks BATS Stocks Latest Stock Ideas MarketBeat Week in Review – 07/07 - 07/11 Power Solutions International Poised for 75% Upside The Meteoric Rise of Rocket Lab: A Space Stock to Watch Meta and Autonomous Advertising: The Stock's Next Big Tailwind? Super Micro Computer: The Hidden Winner of Soaring Copper Tariffs Nebius Group: Up 385%, Analysts Say It’s Still a Bargain Broadcom Stock: HSBC Sets $400 Target on AI Growth Potential BigBear.ai: Why a 90% Rally Could Be Just the Start Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
